141 related articles for article (PubMed ID: 30288322)
1. Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries.
Maistat L; Kravchenko N; Reddy A
Hepatol Med Policy; 2017; 2():9. PubMed ID: 30288322
[TBL] [Abstract][Full Text] [Related]
2. Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia.
Luhmann N; Champagnat J; Golovin S; Maistat L; Agustian E; Inaridze I; Myint WM; Butsashvili M; Bouscaillou J
Int J Drug Policy; 2015 Nov; 26(11):1081-7. PubMed ID: 26342273
[TBL] [Abstract][Full Text] [Related]
3. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
[TBL] [Abstract][Full Text] [Related]
4. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
Maticic M; Zorman JV; Gregorcic S; Schatz E; Lazarus JV
Harm Reduct J; 2019 May; 16(1):32. PubMed ID: 31072401
[TBL] [Abstract][Full Text] [Related]
5. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
Maticic M; Videcnik Zorman J; Gregorcic S; Schatz E; Lazarus JV
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S14. PubMed ID: 25252635
[TBL] [Abstract][Full Text] [Related]
6. Syphilis, hepatitis C and HIV in Eastern Europe.
Bailey H; Turkova A; Thorne C
Curr Opin Infect Dis; 2017 Feb; 30(1):93-100. PubMed ID: 27755143
[TBL] [Abstract][Full Text] [Related]
7. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P
Lancet; 2016 Sep; 388(10050):1228-48. PubMed ID: 27427455
[TBL] [Abstract][Full Text] [Related]
8. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
9. State of viral hepatitis care in 16 countries of Central and Eastern European Region.
Chkhartishvili N; Holban T; Simonović Babić J; Alexiev I; Matičič M; Kowalska J; Horban A;
Cent Eur J Public Health; 2019 Sep; 27(3):212-216. PubMed ID: 31580556
[TBL] [Abstract][Full Text] [Related]
10. HIV and HCV among people who inject drugs in Central Asia.
Walsh N; Maher L
Drug Alcohol Depend; 2013 Nov; 132 Suppl 1():S37-40. PubMed ID: 23906997
[TBL] [Abstract][Full Text] [Related]
11. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
12. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
[TBL] [Abstract][Full Text] [Related]
13. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
14. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
Ford N; Wiktor S; Kaplan K; Andrieux-Meyer I; Hill A; Radhakrishnan P; Londeix P; Forette C; Momenghalibaf A; Verster A; Swan T
Int J Drug Policy; 2015 Nov; 26(11):1088-93. PubMed ID: 26074094
[TBL] [Abstract][Full Text] [Related]
15. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
16. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
18. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.
Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J
J Hepatol; 2018 Nov; 69(5):1188-1196. PubMed ID: 29959953
[TBL] [Abstract][Full Text] [Related]
19. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
20. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
